NCT00323622 - Long-Term Follow-up of Children for a 2-Year Period to Confirm the Safety and Immunogenicity of GSK 257049 Vaccine | Biotech Hunter

Enrollment

1,737

Participants

Timeline

Start Date

April 30, 2005

Primary Completion Date

May 31, 2007

Study Completion Date

May 31, 2007

Conditions

Malaria

Interventions

BIOLOGICAL

GSK Biologicals' candidate Plasmodium falciparum malaria vaccine 257049

IM injection in the deltoid muscle

BIOLOGICAL

Engerix™-B

IM injection in the deltoid muscle

BIOLOGICAL

Hiberix®

IM injection in the deltoid muscle

BIOLOGICAL

Prevnar™

IM injection in the deltoid muscle

DRUG

sulfadoxine-pyrimethamine

1 dose orally per day for 3 days, 4 weeks prior to onset of surveillance

DRUG

amodiaquine

1 dose orally per day for 3 days, 4 weeks prior to onset of surveillance

Trial Locations (1)

GSK Investigational Site, Maputo